The 13 most recent market catalysts affecting $AGL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Bernstein Upgrades Agilon Health to Outperform, Raises Price Target to $125
Bernstein analyst Lance Wilkes upgraded Agilon Health (AGL) from Market Perform to Outperform and raised the price target from $86 to $125. This is a significant positive developme…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Underweight on Agilon Health, Raises Price Target to $85
JP Morgan analyst Lisa Gill maintained an 'Underweight' rating on Agilon Health (AGL), which suggests a continued cautious outlook on the stock's potential for outperformance. Howe…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $146
Wells Fargo analyst Stephen Baxter has maintained an 'Overweight' rating on Agilon Health (AGL) and raised the price target from $141 to $146. This action signals continued bullish…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Upgrades Agilon Health to Neutral, Raises Price Target to $115
Citigroup analyst Daniel Grosslight upgraded Agilon Health (AGL) from a 'Sell' to a 'Neutral' rating and raised the price target from $105 to $115. This change in analyst sentiment…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Maintains Hold on Agilon Health, Raises Price Target to $112
Truist Securities analyst Jailendra Singh maintained a 'Hold' rating on Agilon Health (AGL) but substantially raised the price target from $67 to $112. This action indicates that w…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Benchmark Maintains Buy on Agilon Health, Raises Price Target to $140
Benchmark analyst Bill Sutherland maintained a 'Buy' rating on Agilon Health (AGL) and raised the price target from $95 to $140. This substantial increase in the price target indic…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Equal-Weight on Agilon Health, Raises Price Target to $111
Barclays analyst Andrew Mok has maintained an 'Equal-Weight' rating on Agilon Health (AGL) but has substantially raised the price target from $81 to $111. This indicates that while…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 95
Agilon Health Lowers FY2026 Sales Guidance from $5.680B-$5.805B to $1.445B-$1.475B vs $5.719B Est
Agilon Health (AGL) has announced a staggering reduction in its FY2026 sales guidance, slashing it from an initial $5.680B-$5.805B down to $1.445B-$1.475B. This represents a cut of…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
CORRECTION: Agilon Health Raises FY2026 Sales Guidance from $5.680B-$5.805B to $5.775B-$5.860B vs $5.719B Est
Agilon Health (AGL) announced a correction to its previous FY2026 sales guidance, increasing the range from $5.680 billion-$5.805 billion to $5.775 billion-$5.860 billion. This upw…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Agilon Health Q2 EPS $1.04 Beats $(0.75) Estimate, Sales $1.495B Beat $1.450B Estimate
Agilon Health (AGL) announced Q2 earnings per share of $1.04, dramatically surpassing the analyst consensus estimate of a $(0.75) loss. This represents a substantial 238.67% beat a…
Jul 23, 2026
Corporate Catalyst
Bearish
Impact 75
agilon health shares are trading lower after Citigroup downgraded the stock from Neutral to Sell.
The downgrade of agilon health (AGL) from Neutral to Sell by Citigroup is a significant corporate catalyst. Analyst downgrades, especially from major institutions, often trigger im…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $141
Wells Fargo analyst Stephen Baxter maintained an 'Overweight' rating on Agilon Health and nearly doubled its price target from $72 to $141. This significant upgrade indicates a str…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.